Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Intellia Therapeutics Inc Logo

ARKK Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
August 3, 2022
SELL82.515k0.0621%ARKK
July 14, 2022
SELL60.190k0.0438%ARKK
April 14, 2022
BUY43.968k0.0243%ARKK
April 13, 2022
BUY3.543k0.002%ARKK
April 12, 2022
BUY18.178k0.0105%ARKK

Key Statistics

DateAugust 04, 2022Revenue
Expected$9.42m
Actual$14.03m
EPS
Expected-$1.31
Actual-$1.33
🕵🏼Found In🏷Last Price
ARKKARKG$60.41
⚖️Weighting🧢Market Cap
4.14%$4.59b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
11101.28
🏋️‍♀️Weight Rank Across All Funds🌏Country
11🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$62.048.49%
Description
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Website
www.intelliatx.com